



نتقدم بثقة
Moving Forward
with Confidence

رؤية عمان
2040
Oman Vision

To:

Pharmacist Incharge, Armed Forces Hospital (AT Khoudh & Salah)
Director of Pharmaceutical Care, Royal Hospital
Director of Pharmaceutical Care, Khoula Hospital
Pharmacist Incharge, Al Nahda Hospital
Director of Pharmaceutical Care, DGHS, Muscat Governorate
Director of Pharmaceutical Care, DGHS, Al Dakhliya Governorate
Director of Pharmaceutical Care, DGHS, South Batinah Governorate
Director of Pharmaceutical Care, DGHS, North Batinah Governorate
Director of Pharmaceutical Care, DGHS, AI Dhahira Governorate
Director of Pharmaceutical Care, DGHS, North Sharqiya Governorate
Director of Pharmaceutical Care, DGHS, South Sharqiya Governorate
Director of Pharmaceutical Care, DGHS, Musandam Governorate
Director of Pharmaceutical Care, DGHS, Dhofar Governorate
Director of Pharmaceutical Care, DGHS, Al Wusta Governorate
Director of Pharmaceutical Care, DGHS, Buraimi Governorate
Director of Pharmaceutical Care, DGMS
Pharmacist Incharge, Al Massarah Hospital
HOD, Pharmacy Department, Sultan Qaboos University Hospital
Pharmacist Incharge, Royal Oman Police
Pharmacist Incharge, The Diwan
Pharmacist Incharge, The Sultan's Special Force
Pharmacist Incharge, Internal Security Services
Pharmacist Incharge, Petroleum Development of Oman
Pharmacist Incharge, LNG Oman

After Compliments,

Kindly find attached our Circular No **26** dated **05/03/2026** Regarding Update to Health Care Professionals About Falsified Mounjaro KwikPen 15mg pre-filled pens.

Copy to:

- Director of Pharmacovigilance Department, DSC
- Director of Medicine Registration Department, DSC
- Director of Regulatory Compliance Department, DSC
- Director of Central Quality Control Lab., DSC
- Director of Medical Device Department, DSC
- Section Head of Medicine Safety Evaluation
- Section Head of Quality Problems and Medication Errors.
- Section Head of Pharmacovigilance
- Section Head of Clinical Trials



DSC
مركز سلامة الدواء
Drug Safety Center



ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩

P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489

@DSCPHO Email: dscpho@moh.gov.om



Circular No. 26 /2026

15 -09-1447 H
05 -03-2026

نتقدم بثقة
Moving Forward
with Confidence



Subject: Falsified Mounjaro KwikPen 15mg pre-filled pens

The Drug Safety Center (DSC) would like to share a new safety information published by Medicine and Health products Regulatory Agency (MHRA) regarding **Falsified Mounjaro KwikPen 15mg pre-filled pens**.

Mounjaro (tirzepatide) is a dual glucagon-like peptide-1 (GLP-1)/ glucose- dependent insulinotropic polypeptide (GIP) receptor agonist authorised for the treatment of type 2 diabetes mellitus and weight management in patients who are overweight or obese.

A **falsified version of Mounjaro (tirzepatide) KwikPen 15mg solution for injection** has been found supplied through one online pharmacy in the UK. The falsified product is labelled with batch **D873576** and applies to Mounjaro KwikPen 15mg solution for injection in pre-filled pen only.

Advice for Healthcare Professionals:

- do not supply Mounjaro KwikPen 15mg solution for injection in pre-filled pens with batch number **D873576**, all 15mg pens with this batch number are falsified (see pictures of product below).
- this is a legitimate batch number for genuine Mounjaro KwikPen 7.5mg, and pens at this strength are not impacted.
- quarantine all remaining stock that has the affected dose and batch number and return it to your supplier.
- it is likely that the substance in the pens is tirzepatide, however the pens are not of the quality and safety standards of legitimate pens and are not safe to use.
- all pens identified to date have had a faulty mechanism.
- if a patient reports a faulty 15mg pen, ask them to check the batch number and instruct them to discontinue use of the pen if it matches the above-mentioned batch number. Patients should always be advised not to try and extract doses from any defective pen.
- patients should be advised on signs and symptoms of allergic reactions, infection or sepsis to look out for and any treatment should be provided accordingly.
- patients may require replacement medication in order to continue their course of treatment.



DSC
مركز سلامة الدواء
Drug Safety Center



ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩

P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489

✉ @DSCPHO Email: dscpho@moh.gov.om




نتقدم بثقة
Moving Forward
with Confidence

رؤية عمان
2040
Oman Vision

Advice for Healthcare Professionals to Provide to Patients:

- check the batch number on any Mounjaro KwikPen 15mg pre-filled pens you have been dispensed.
- if you have a 15mg pen with batch number **D873576**, do not use the pen. Pictures of the product are provided below.
- if you are unsure of how to identify the pen, or are unsure on whether you have administered an affected batch and have any questions please speak to a healthcare professional.
- if you have administered injections using the pen already, please be reassured that, on the basis of the cases reviewed to date, the risk to you is low.
- if you have administered injections, and you are experiencing any unusual symptoms that you are concerned about, seek immediate medical attention.



Call to report:

Mounjaro (tirzepatide) is registered in Oman. Healthcare professionals, patients, and caregivers are requested to report any suspected falsified products or adverse drug reactions associated with Mounjaro (tirzepatide) to the Pharmacovigilance Department at the Drug Safety Center.

Ph. Ibrahim Nasser Al Rashdi
Director General



DSC
مركز سلامة الدواء
Drug Safety Center



ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
@DSCPHO Email: dscpho@moh.gov.om